Skip to main content

COVID 19 Updates from RheumNow

Post 9/11 Autoimmune Disease Risk

The 9/11/01 terrorist attach on the World Trade Center (WTC)  resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage.  Arthritis & Rheumatology reports that dust cloud exposure among responders and

RheumNow Podcast – The Beginning of Something Else (4.10.20)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Coagulopathy and Antiphospholipid Antibodies with Covid-19

The New England Journal of Medicine has featured a report of three COVID infected patients, who developed peripheral and central infarcts with a antiphospholipid antibodies. 

Urgent or Not

Rheumatologic practice has been turned upside down as a consequence of the COVID-19 crisis. 

TNR - Grand Rounds: Safety of Biologics & New Agents

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

Incubation Period for COVID-19

The incubation period for coronavirus disease 2019 (COVID-19) has important implications for surveillance and control activities. The Annals of Internal Medicine reports a pooled analysis of confirmed COVID-19 cases January 4, 2020 and February 24, 2020.

COVID-19 Susceptibility: Why Do Some Become So Ill?

Why are some people with the SARS-CoV-2 coronavirus that causes COVID-19 so ill while others barely notice the infection?

NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic

On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.

COVID Town Hall Meeting for Rheumatology

On Thursday, April 2nd, RheumNow hosted its' first Town Hall Meeting for Rheumatologist, with this 90 minute discussion devoted to the COVID-19 crisis as it affects Rheumatologists. 

RheumNow Podcast – Pandemic Numbers (4.3.20)

Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:

Universal Masking for COVID?

In early March 2020, there were widespread recommendations that wearing routine "surgical masks" by the public sector was not likely to be helpful or advisable.

Some Good Things, During the Time of COVID-19

It is not hyperbole to acknowledge that the COVID-19 pandemic has changed the world, inflicting pain and suffering to many, and inconvenience to all.

Social

@kristenyoung @rheum_covid project on impact of COVID-19 on our trainees. Love the graphics by @EBRheum . Negatives are physical health, stress levels, and burnout all ⬆️ . Positives? Trainees did feel supported by programmes. Abstr#0485 #ACR21 @RheumNow https://t.co/kXQ1AUNrgb
Richard Conway @RichardPAConway ( View Tweet )
2 years 5 months ago
My exclusive interview w/the GRA Powerhouse! What are they studying next? 👉impact of COVID policies on Rheum pts 👉pt's perception w/COVID vaccines 👉COVID risk calculator 👉long haulers w/ rheum dz 👉breakthrough infections @rheumnow https://t.co/dVLayNchHT @rheum_covid https://t.co/B1KIjxYt15
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 5 months ago
Abs 457 #ACR21 @rheumnow Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients - Most (90%) developed Ab response but with reduced titers - GC users including some low dose mounted low responses - TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc
Akhil Sood MD @AkhilSoodMD ( View Tweet )
2 years 5 months ago
Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?

Olga Petryna @DrPetryna ( View Tweet )

2 years 5 months ago
#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow
2 years 5 months ago
The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies after the #COVID19 vaccine, but it was reduced compared to that of generally healthy people. #ACR21 #Plenary @alhkim https://t.co/KdWtIuuOtA
CreakyJoints.org @CreakyJoints ( View Tweet )
2 years 5 months ago
plenary I. #ACR21 Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA
Marie Kuchynski MD @Doctorkuch ( View Tweet )
2 years 5 months ago
@alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf
Richard Conway @RichardPAConway ( View Tweet )
2 years 5 months ago
Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7
Olga Petryna @DrPetryna ( View Tweet )
2 years 5 months ago
#ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas ⭐️Prosp observ: pre-vax▶️5 mo. ⭐️ 90% +Ab responses, but ⬇️ titer ⭐️MMF 21x⬇️ titer, MTX 4.4x⬇️, AZA 3.5⬇️ ⭐️BCDT: 58, JAK: 2.6, TNF 2.3 ⭐️GC ⬇️ even on <5mg! https://t.co/BGU4CP9M0s @Rheumnow #ACRbest https://t.co/7QhsTGTwnZ
2 years 5 months ago